CHEMOTHERAPY IN OSTEOSARCOMA - BASIS FOR APPLICATION AND ANTAGONISM TO IMPLEMENTATION - EARLY CONTROVERSIES SURROUNDING ITS IMPLEMENTATION

Citation
N. Jaffe et al., CHEMOTHERAPY IN OSTEOSARCOMA - BASIS FOR APPLICATION AND ANTAGONISM TO IMPLEMENTATION - EARLY CONTROVERSIES SURROUNDING ITS IMPLEMENTATION, Hematology/oncology clinics of North America, 9(4), 1995, pp. 825-840
Citations number
79
Categorie Soggetti
Oncology,Hematology
ISSN journal
08898588
Volume
9
Issue
4
Year of publication
1995
Pages
825 - 840
Database
ISI
SICI code
0889-8588(1995)9:4<825:CIO-BF>2.0.ZU;2-B
Abstract
Chemotherapy in osteosarcoma has had a major impact in attaining metas tasis-free survival, and the cure rates with the use of modern regimen s range from 65% to 75%. Preoperative chemotherapy has facilitated sur gical resection of the primary tumor, rendering increased numbers of c andidates for limb salvage. The effects on the primary tumor may be us ed as a predictive factor in determining outcome.